Targeting Cardiac Fibrosis in Diabetic Heart Failure: The Role of the EZH2, AMPK, and PPAR-γ Pathways (Diabetes Metab J 2024;48:716-29).
作者信息
Lee Jooyeop, Moon Joon Ho
机构信息
Department of Internal Medicine, Armed Forces Yangju Hospital, Yangju, Korea.
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
出版信息
Diabetes Metab J. 2024 Nov;48(6):1176-1178. doi: 10.4093/dmj.2024.0551. Epub 2024 Nov 21.
Abstract
摘要
相似文献
1
Targeting Cardiac Fibrosis in Diabetic Heart Failure: The Role of the EZH2, AMPK, and PPAR-γ Pathways (Diabetes Metab J 2024;48:716-29).靶向糖尿病性心力衰竭中的心脏纤维化：EZH2、AMPK和PPAR-γ信号通路的作用（《糖尿病与代谢杂志》2024年；48:716 - 29）
Diabetes Metab J. 2024 Nov;48(6):1176-1178. doi: 10.4093/dmj.2024.0551. Epub 2024 Nov 21.
2
Diabetes Promotes Myocardial Fibrosis via AMPK/EZH2/PPAR-γ Signaling Pathway.糖尿病通过 AMPK/EZH2/PPAR-γ 信号通路促进心肌纤维化。
Diabetes Metab J. 2024 Jul;48(4):716-729. doi: 10.4093/dmj.2023.0031. Epub 2024 Feb 27.
3
Diabetes Promotes Myocardial Fibrosis via AMPK/EZH2/PPAR-γ Signaling Pathway (Diabetes Metab J 2024;48:716-29).糖尿病通过AMPK/EZH2/PPAR-γ信号通路促进心肌纤维化（《糖尿病与代谢杂志》2024年；48:716 - 29）
Diabetes Metab J. 2024 Nov;48(6):1181-1182. doi: 10.4093/dmj.2024.0675. Epub 2024 Nov 21.
4
PIAS1 alleviates diabetic peripheral neuropathy through SUMOlation of PPAR-γ and miR-124-induced downregulation of EZH2/STAT3.PIAS1通过PPAR-γ的类泛素化修饰以及miR-124诱导的EZH2/STAT3下调来减轻糖尿病周围神经病变。
Cell Death Discov. 2021 Dec 2;7(1):372. doi: 10.1038/s41420-021-00765-w.
5
Research into the anti-pulmonary fibrosis mechanism of Renshen Pingfei formula based on network pharmacology, metabolomics, and verification of AMPK/PPAR-γ pathway of active ingredients.基于网络药理学、代谢组学及活性成分 AMPK/PPAR-γ 通路验证的人参平肺方抗肺纤维化机制研究。
J Ethnopharmacol. 2023 Dec 5;317:116773. doi: 10.1016/j.jep.2023.116773. Epub 2023 Jun 10.
6
Si-Miao-Yong-An decoction preserves cardiac function and regulates GLC/AMPK/NF-κB and GLC/PPARα/PGC-1α pathways in diabetic mice.四物汤通过调控 GLC/AMPK/NF-κB 和 GLC/PPARα/PGC-1α 通路改善糖尿病小鼠心功能
Biomed Pharmacother. 2020 Dec;132:110817. doi: 10.1016/j.biopha.2020.110817. Epub 2020 Oct 14.
7
Gentiopicroside Ameliorates Diabetic Peripheral Neuropathy by Modulating PPAR- Γ/AMPK/ACC Signaling Pathway.龙胆苦苷通过调节PPAR-Γ/AMPK/ACC信号通路改善糖尿病周围神经病变。
Cell Physiol Biochem. 2018;50(2):585-596. doi: 10.1159/000494174. Epub 2018 Oct 11.
8
Targeting EZH1 and EZH2 contributes to the suppression of fibrosis-associated genes by miR-214-3p in cardiac myofibroblasts.靶向EZH1和EZH2有助于miR-214-3p在心肌成纤维细胞中抑制纤维化相关基因。
Oncotarget. 2016 Nov 29;7(48):78331-78342. doi: 10.18632/oncotarget.13048.
9
Catalpol Ameliorates Insulin Sensitivity and Mitochondrial Respiration in Skeletal Muscle of Type-2 Diabetic Mice Through Insulin Signaling Pathway and AMPK/SIRT1/PGC-1α/PPAR-γ Activation.梓醇通过激活胰岛素信号通路和 AMPK/SIRT1/PGC-1α/PPAR-γ 改善 2 型糖尿病小鼠骨骼肌胰岛素敏感性和线粒体呼吸功能。
Biomolecules. 2020 Sep 24;10(10):1360. doi: 10.3390/biom10101360.
10
Carbon monoxide (from CORM-2) inhibits high glucose-induced ICAM-1 expression via AMP-activated protein kinase and PPAR-gamma activations in endothelial cells.一氧化碳（来自 CORM-2）通过激活内皮细胞中的 AMP 激活的蛋白激酶和过氧化物酶体增殖物激活受体 γ 抑制高糖诱导的细胞间黏附分子-1 的表达。
Atherosclerosis. 2009 Dec;207(2):405-11. doi: 10.1016/j.atherosclerosis.2009.05.008. Epub 2009 May 21.
本文引用的文献
1
Diabetes Promotes Myocardial Fibrosis via AMPK/EZH2/PPAR-γ Signaling Pathway.糖尿病通过 AMPK/EZH2/PPAR-γ 信号通路促进心肌纤维化。
Diabetes Metab J. 2024 Jul;48(4):716-729. doi: 10.4093/dmj.2023.0031. Epub 2024 Feb 27.
2
Mechanisms of action and resistance in histone methylation-targeted therapy.组蛋白甲基化靶向治疗的作用机制和耐药性。
Nature. 2024 Mar;627(8002):221-228. doi: 10.1038/s41586-024-07103-x. Epub 2024 Feb 21.
3
Epicardial Adipose Tissue and Heart Failure, Friend or Foe?心外膜脂肪组织与心力衰竭：敌是友？
Diabetes Metab J. 2024 May;48(3):373-384. doi: 10.4093/dmj.2023.0190. Epub 2024 Feb 2.
4
Primordial Drivers of Diabetes Heart Disease: Comprehensive Insights into Insulin Resistance.糖尿病性心脏病的原始驱动因素：对胰岛素抵抗的全面见解
Diabetes Metab J. 2024 Jan;48(1):19-36. doi: 10.4093/dmj.2023.0110. Epub 2024 Jan 3.
5
Heart failure in diabetes.糖尿病性心力衰竭。
Metabolism. 2021 Dec;125:154910. doi: 10.1016/j.metabol.2021.154910. Epub 2021 Oct 8.
6
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.达格列净治疗射血分数降低的心力衰竭患者。
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
7
Pioglitazone Alleviates Cardiac Fibrosis and Inhibits Endothelial to Mesenchymal Transition Induced by Pressure Overload.吡格列酮减轻压力超负荷诱导的心脏纤维化并抑制内皮-间充质转化
Cell Physiol Biochem. 2018;45(1):26-36. doi: 10.1159/000486220. Epub 2017 Dec 22.
8
Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients.比较患有糖尿病和心力衰竭的患者使用二甲双胍的安全性和有效性：涉及 34000 名患者的观察性研究的系统评价。
Circ Heart Fail. 2013 May;6(3):395-402. doi: 10.1161/CIRCHEARTFAILURE.112.000162. Epub 2013 Mar 18.
9
Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy.吡格列酮可减轻糖尿病肾病大鼠模型的心肌纤维化和肥大。
J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):324-33. doi: 10.1177/1074248411431581. Epub 2012 Jan 18.
10
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.噻唑烷二酮类药物的心血管系统比较作用：观察性研究的系统评价和荟萃分析。
BMJ. 2011 Mar 17;342:d1309. doi: 10.1136/bmj.d1309.
Zotero 插件